Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
De Lemos-Bonotto M et al. | A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment. | 2018 | Eur J Gastroenterol Hepatol | pmid:29227329 |
Almeida-Paulo GN et al. | Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant. | 2018 | Pharmacogenomics J. | pmid:28094348 |
Asano T et al. | The utility of FDG-PET/CT imaging in the evaluation of multicentric reticulohistiocytosis: A case report. | 2018 | Medicine (Baltimore) | pmid:30113451 |
Belaiche S et al. | Factors associated with the variability of calcineurin inhibitor blood levels in kidney recipients grafted for more than 1Â year. | 2018 | Fundam Clin Pharmacol | pmid:29069531 |
Wang DD et al. | Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. | 2018 | J Clin Pharm Ther | pmid:29766530 |
Krzyżowska K et al. | Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction? | 2018 | Biomed Res Int | pmid:29651435 |
Takeuchi K et al. | Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis. | 2018 | Dig Dis | pmid:29050007 |
Mashiah J et al. | Topical pimecrolimus for paediatric cutaneous mastocytosis. | 2018 | Clin. Exp. Dermatol. | pmid:29460435 |
Li A et al. | Atopic keratoconjunctivitis: A diagnostic dilemma-a case report. | 2018 | Medicine (Baltimore) | pmid:29668589 |
Dheer D et al. | Tacrolimus: An updated review on delivering strategies for multifarious diseases. | 2018 | Eur J Pharm Sci | pmid:29277665 |